BioCentury
ARTICLE | Finance

Chinese investment in U.S. biotechs to slow further

Why Chinese VC investments in U.S. biotechs will likely continue to taper off in 2019

August 16, 2019 10:16 PM UTC

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life science funds have started to decline.

Last year was a high watermark for U.S. biotechs raising money from Chinese VCs. According to BioCentury’s BCIQ database, in 2018, U.S. companies raised $4.2 billion across 66 deals that included a Chinese VC...